Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.

2002-03-01

European Heart Journal , Volume 23 - Issue 6 p. 444- 457

Additional Metadata
Keywords	Administration, Oral, Cardiovascular Diseases/drug therapy, Clinical Trials, Humans, Platelet Aggregation Inhibitors/pharmacology/therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors, Research Support, Non-U.S. Gov't
Persistent URL	doi.org/10.1053/euhj.2001.2751, hdl.handle.net/1765/13020
Journal	European Heart Journal
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Leebeek, F., Boersma, E., Cannon, C. P., Simoons, M.& van de Werf, F. (2002). Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. In European Heart Journal (Vol. 23, Number 6, pp. 444–457).https://doi.org/10.1053/euhj.2001.2751

Publication